Xin Lang Cai Jing·2025-11-10 09:30Core Viewpoint - The news highlights the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., emphasizing its strong international revenue and the impact of RMB depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [2]. - The company's main business includes the heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [2][7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On November 10, the stock price of Hepalink increased by 0.90%, with a trading volume of 45.0469 million yuan and a turnover rate of 0.29%, bringing the total market capitalization to 18.15 billion yuan [1]. - The stock has seen a net outflow of 1.201 million yuan from major funds today, indicating a lack of strong buying interest [4][5]. Technical Analysis - The average trading cost of the stock is 11.57 yuan, with the current price near a support level of 12.33 yuan, suggesting potential for a rebound if this level holds [6].